Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.

doi:10.1016/j.jcma.2013.05.007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.

Journal of the Chinese Medical Association : JCMA - 1 Sept 2013

Song Zhengbo, Lin Baochai, Shao Lan, Zhang Yiping

Abstract excerpt

BACKGROUND: Adenosquamous carcinoma (ASC) of the lung is a rare subtype of nonsmall-cell lung cancer (NSCLC). To date, the efficacious targeted therapy for advanced ASC remains unclear and the epidermal growth factor receptor (EGFR) mutation rate is not well known. METHODS: We retrospectively reviewed clinical information of patients with ASC who were treated with gefitinib or erlotinib at Zhejiang Cancer...

Topics

Antineoplastic Agents
Carcinoma, Adenosquamous
ErbB Receptors
Erlotinib Hydrochloride
Female
Gefitinib
Humans
Lung Neoplasms
Male
Middle Aged
Mutation
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Quinazolines
Retrospective Studies
Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 23769878
DOI: 10.1016/j.jcma.2013.05.007

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics